CD8A and melanoma: After the DC vaccines, 18 of 31 (58%) tested had developed increased T cell responses over baseline to vaccine-encoded melanoma antigens (Tyrosinase: 7 CD8+/4 CD4+; MART-1: 6 CD8+/7 CD4+; MAGE-A6: 4 CD8+/ 2 CD4+ responses across 18 pt).